Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536017 | 0.77 | CA2 (0.30) | — | |
| SCHEMBL535252 | 0.77 | S100A4 (0.39) | KDM4EHTT | |
| SCHEMBL2540684 | 0.73 | KDM4E (0.38) | SLC6A2SLC6A4KDM4EGLAALDH1A1 | |
| SCHEMBL754025 | 0.73 | KDM4E (0.41) | SLC6A2SLC6A4KDM4EGLAALDH1A1 | |
| SCHEMBL16052518 | 0.70 | PYCR1 (0.42) | LMNA | |
| SCHEMBL6739825 | 0.70 | KDM4E (0.38) | KDM4EGLAALDH1A1KMT2A | |
| SCHEMBL29429850 | 0.68 | ALDH1A1 (0.39) | KDM4EGLAALDH1A1KMT2A | |
| SCHEMBL16429762 | 0.67 | USP28 (0.49) | ALDH1A1LMNAHTTKMT2A | |
| SCHEMBL3923194 | 0.67 | CYP2A6 (0.46) | KDM4EGLAALDH1A1KMT2A | |
| SCHEMBL30673419 | 0.67 | KDM4E (0.42) | KDM4EGLAALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-21 | — | — | US | disclosed |
| US-9273013-B2 | Quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-01 | — | — | US | disclosed |
| US-20130178624-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-11 | — | — | US | disclosed |
| US-8394786-B2 | Quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| EP-1633365-B1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-08 | — | — | EP | disclosed |
| EP-2305687-A1 | Quinazoline derivatives | Janssen Pharmaceutica NV (BE) | 2011-04-06 | — | — | EP | disclosed |
| US-20100105668-A1 | Quinazoline derivatives | FREYNE EDDY JEAN EDGARD | 2010-04-29 | — | — | US | disclosed |
| US-7648975-B2 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-19 | — | — | US | disclosed |
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178624-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | SLC6A2 1376/4885SLC6A4 979/4885KDM4E 3453/4885 |
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | NR1H3, NR1H2, NCOA3 | SLC6A2 2948/4885SLC6A4 1836/4885KDM4E 2513/4885 |
| US-20100105668-A1 | Quinazoline derivatives | NR1H2, NR1H3, NR3C2 | SLC6A2 1354/4885SLC6A4 958/4885KDM4E 3623/4885 |
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | SLC6A2 733/4885SLC6A4 601/4885KDM4E 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.